Laboratory-Grade Aromatase Inhibition Research
Femistra 1 mg is a pharmaceutical-grade anastrozole preparation manufactured by Zydus Healthcare, specifically formulated for in-vitro laboratory research applications. Anastrozole is a non-steroidal aromatase inhibitor that competitively inhibits the aromatase enzyme (CYP19A1), effectively reducing estrogen biosynthesis in experimental models. This compound represents one of the most extensively studied aromatase inhibitors in endocrine research, offering researchers a reliable tool for investigating estrogen-dependent pathways and hormonal regulation mechanisms.
As part of our comprehensive research chemical catalogue at Stroid UK Shop, Femistra provides researchers with access to pharmaceutical-standard anastrozole for advanced endocrinological studies. Unlike research compounds found in our SARMs collection or peptide research tools, this aromatase inhibitor offers unique insights into estrogen synthesis modulation, making it invaluable for studies examining hormonal balance and receptor interactions.
Endocrine Research Applications
Researchers investigating aromatase inhibition mechanisms utilise Femistra to examine the relationship between estrogen synthesis and various physiological processes. The compound’s selective inhibition of the aromatase enzyme allows for precise control over estrogen production in experimental models, enabling detailed analysis of estrogen-dependent cellular responses. Studies have demonstrated anastrozole’s ability to achieve significant aromatase inhibition, making it a reference standard in endocrine research protocols. Laboratory investigations often focus on understanding how aromatase inhibition affects cellular proliferation, gene expression patterns, and metabolic pathways in estrogen-responsive tissues. The pharmaceutical formulation ensures consistent compound delivery and reliable experimental outcomes across research protocols.
Research Compound Specifications
| Active Compound | Anastrozole |
|---|---|
| Concentration | 1 mg per tablet |
| Manufacturer | Zydus Healthcare Ltd. |
| CAS Number | 120511-73-1 |
| Molecular Formula | C₁₇H₁₉N₅ |
| Molecular Weight | 293.37 g/mol |
| Storage Requirements | Room temperature, dry environment |
| Research Category | Aromatase Inhibitor |
This pharmaceutical-grade preparation is available through our specialised aromatase inhibitor research section, ensuring researchers have access to verified compounds for their endocrine studies. Each batch undergoes rigorous quality control testing to maintain research-grade standards and experimental reliability.
Research Compliance and Laboratory Use
Femistra 1 mg is manufactured exclusively for in-vitro research purposes and laboratory applications. This compound is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must ensure proper handling protocols, appropriate storage conditions, and adherence to institutional safety guidelines when conducting studies with this aromatase inhibitor. All experimental work should be performed under appropriate supervision with proper documentation of research methodologies and outcomes.
